When doctors look for ways to predict how a patient will respond to treatment, they often look at the immune system. A new review of three studies suggests that a specific type of immune cell, known as CD103+ tumor-infiltrating lymphocytes, could be a key indicator of survival for people with bladder cancer.
The data showed that patients with a high density of these cells lived longer. This link was especially strong for those with muscle-invasive bladder cancer who underwent surgery followed by chemotherapy. While the trend was less clear for those with metastatic urothelial carcinoma, the presence of these cells remains a significant point of interest for researchers.
It is important to note that this finding is currently used to generate new ideas for research rather than as a tool for immediate clinical use. The method for measuring these cells is not yet ready for routine use in a doctor's office. Because these results are based on an analysis of existing data, they show a link between cells and survival, not a direct cause.
